Ken Shinomiya, Leader of Asahi Kasei’s Healthcare SectorAsahi Kasei Healthcare Sector Leadership Leading the way for the sector’s continued growth and commitment to improving patient outcomes CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO, April 24, 2025--(BUSINESS WIRE)--Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of its Healthcare Sector succeeding Richard Packer. Under Shinomiya, Asahi Kasei’s Healthcare Sector will further advance its portfolio and global presence of pharmaceuticals, life science, and critical care products and services. Having served as Vice President of Strategy at ZOLL Medical Corporation from fiscal 2016 to fiscal 2017, Shinomiya became Head of the Bioprocess Division of Asahi Kasei Medical in April 2019 and President of Asahi Kasei Medical in April 2023. In April 2025, he was named President of Asahi Kasei Life Science, the successor company to the bioprocess business of Asahi Kasei Medical. With operations focused on products and services that support the manufacture of pharmaceuticals, the life science business has grown globally by ascertaining market needs and business opportunities within the pharmaceutical industry. Under Shinomiya’s leadership, the life science business has successfully expanded from its foundational Planova™ virus removal filters through the addition of contract research organization (CRO) testing services as well as the biologics contract development and manufacturing organization (CDMO) business of Bionova Scientific in the U.S. Asahi Kasei’s Healthcare Sector has dramatically globalized since the 2012 acquisition of ZOLL Medical Corporation with its U.S.-based business platform in critical care. Since then, the Healthcare Sector has accelerated its growth strategy as a diverse global healthcare company by accurately discerning market needs, making proactive investments including M&A, and moving its headquarters to the U.S. in 2023. This has leveraged the strength of Asahi Kasei’s Healthcare business while enhancing global management. Under the new leadership, the Healthcare Sector will continue to execute a long-term strategy to grow its pharmaceutical, life science, and critical care businesses. Guided by its mission to "Improve and save patients’ lives," the sector is committed to delivering innovative therapeutics and medical devices that address unmet medical needs and contribute to better patient outcomes worldwide. It will serve as the main growth driver of the Asahi Kasei Group, targeting operating income of ¥150 billion in 2030. "For over a century, the Asahi Kasei Group has created distinctive business models leveraging creativity and innovation to provide exceptional products and services to the world," said Ken Shinomiya, Leader of Asahi Kasei’s Healthcare Sector. "Our healthcare business exemplifies Asahi Kasei’s unique ability to effectively integrate the advanced, efficiency-oriented management approaches gained through global acquisitions. Moving forward, we will further evolve based on our blended international outlook as we continue to lead the growth and globalization of the Asahi Kasei Group." Story Continues About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Healthcare. Its Healthcare operations include devices and systems for critical care, products and services for the manufacture of biotherapeutics, and a growing portfolio of specialty pharmaceuticals. For more information, visit www.asahi-kasei.com. Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/. View source version on businesswire.com: https://www.businesswire.com/news/home/20250424681712/en/ Contacts North America Contact: Asahi Kasei America Inc. Christian OKeefe [email protected] Europe Contact: Asahi Kasei Europe GmbH Sebastian Schmidt [email protected] View Comments
Ken Shinomiya Becomes Leader of Asahi Kasei’s Healthcare Sector
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...